Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 4/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243300 | 0.90 | USP2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL14706988 | 0.90 | USP2 (0.50) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL31049077 | 0.87 | USP2 (0.45) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL19413505 | 0.87 | USP2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL11993192 | 0.86 | CHRM2 (0.51) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL8305574 | 0.86 | CHRM2 (0.64) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL30970603 | 0.85 | NR1H2 (0.48) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL29536161 | 0.85 | NR1H2 (0.44) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL21146017 | 0.84 | USP2 (0.45) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL30915773 | 0.84 | NR1H2 (0.60) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | CHRM2 1644/4885CHRM1 1111/4885CHRM3 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.